Navigation Links
Potential new therapeutic molecular target to fight cancer
Date:11/1/2007

Researchers at the Virginia Commonwealth University Massey Cancer Center have identified the enzyme sphingosine kinase 2 as a possible new therapeutic target to improve the efficacy of chemotherapy for colon and breast cancer.

In the Nov. 1 issue of the journal Cancer Research, researchers examined human colon and breast cancer cells and established a role of sphingosine kinase 2 (SphK2), an enzyme that forms the potent lipid mediator sphingosine-1-phosphate in the death of cancer cells mediated by the chemotherapeutic drug, doxorubicin.

Doxorubicin is able to kill cancer cells by working with p53, one of the most protective anti-cancer proteins in the human body. However, doxorubicin also relies on p53- independent mechanisms to induce death in colon and breast cancer cells.

Understanding how doxorubicin kills in a p53-independent manner is a major goal of cancer researchers because most cancer cells have mutated p53, said lead author Sarah Spiegel, Ph.D., chair and professor in the VCU Department of Biochemistry and Molecular Biology and co-leader of the cancer center's cancer cell biology program.

According to Spiegel, the study demonstrated that SphK2 is important for p53-independent induction of expression of p21, a cyclin-dependent kinase inhibitor. This p21 regulates the cell cycle, and apoptosis or programmed cell suicide, mediated by doxorubicin. Human colon and breast cancer cells were killed more efficiently by doxorubicin when SphK2 was removed from the cells.

Therefore, the findings suggest that SphK2 influences the balance between cytostasis, and apoptosis of human cancer cells, Spiegel said. Cytostasis refers to the stoppage of cellular growth and multiplication.

Spiegel said that cell death was induced by doxorubicin and decreased p21.

Spiegel, who is internationally recognized for her pioneering work on new lipid mediators that regulate cell growth and cell death, and her colleague
'/>"/>

Contact: Sathya Achia-Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. MetaChip provides quick, efficient toxicity screening of potential drugs
4. Simple drug has the potential to save many lives threatened by malaria
5. Potential treatments for neurofibromatosis
6. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
7. Potential Drug Target For Treating Cocaine Abuse Found
8. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
9. Engineers improve plastics potential for use in implants by linking it to biological material
10. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
11. Improving the potential of cancer vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
(Date:9/2/2014)... -- When you accidentally touch a hot oven, you ... basic neural circuits involved in sensing and responding to ... molecular players. , Duke researchers have made a surprising ... in pain in worms, and have built a structural ... in Nature Communications , may help direct new ...
(Date:9/1/2014)... The quality of the U.S. diet showed some modest ... of a reduction in the consumption of unhealthy trans ... between the rich and the poor. , , An ... and some cancers. Eating a healthy diet is an ... outcomes. Evaluating population trends in diet quality is important ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... been accompanied by more years of perfect health, reveals new research ... . Indeed, a 20-year-old today can expect to live one ... a decade ago, even though life expectancy has grown. From ... 85 doubled, from about a 20 percent chance to a 40 ...
... BOSTON Boston University biology professor Richard Primack, ... completed an analysis of the changing arrival dates of ... Henry David Thoreau from the 1850,s. This research builds ... plants in Concord respond rapidly to temperature and are ...
... 2010 Elsevier ( www.elsevier.com ), a world-leading ... and services, today announced that as a result ... HealthMash, is now available on SciVerse Applications beta ... to provide insights to scientific researchers with relevant ...
Cached Biology News:We spend more time sick now than a decade ago 2We spend more time sick now than a decade ago 3WebLib develops application for Elsevier's SciVerse applications 2
(Date:9/2/2014)... Washington, USA (PRWEB) September 02, 2014 ... of Light and Light-based Technologies (IYL 2015) visionary ... from SPIE, the international society for optics and ... presented to Levinson and Dudley along with other awards ... the Society won by James Harrington, during a gala ...
(Date:9/2/2014)... Oregon chemist Geraldine Richmond, have tapped oil and ... called peptoid nanosheets that mimic complex biological mechanisms ... week in a paper placed online ahead of ... Academy of Sciences -- is expected to ... nanosheets that can be used in a broad ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Weisel Partners 2007 Healthcare Conference will be ... the Investors section of the Company,s,website, ... ) The presentation will review recent ...
... ERES ), a leading provider of centralized,electrocardiographic ... Michael J. McKelvey, the Company,s President and,Chief Executive ... will present at the Thomas Weisel Healthcare Conference ... the Phillips Room at The Four Seasons,Hotel in ...
... COMPLETED ... ... LOR; AMEX: LRP), a biopharmaceutical company specializing,in the research and development ... completion of a proof of,concept clinical trial in Acute Myeloid Leukemia ...
Cached Biology Technology:Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th 2eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th 3Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 2Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 3Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 4Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 5
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: